Literature DB >> 7793236

Lamotrigine as an add-on drug in typical absence seizures.

C D Ferrie1, R O Robinson, C Knott, C P Panayiotopoulos.   

Abstract

INTRODUCTION: Lamotrigine is licensed in many countries for use in patients with partial seizures. Evidence suggests that it may also be effective in generalised epilepsies. MATERIAL &
METHODS: We analysed retrospectively our patients with idiopathic generalised epilepsy with refractory absences.
RESULTS: Fifteen patients with idiopathic generalised epilepsies were identified who had been treated with lamotrigine for 3 months or more. All patients were also treated with sodium valproate. Fourteen patients had active absences. Nine (64%) had a total or virtual cessation of absences and in a further patient they became milder and less frequent. One patient reported an increase in seizures. The effective dose of lamotrigine was 1.6-3.0 mg/kg/day in children and 25-50 mg/day in adults. Patients who responded did so after the first or second dose. Lamotrigine was well tolerated.
CONCLUSION: Low-dose lamotrigine added to sodium valproate appears to be effective in typical absence seizures. A therapeutic interaction of the two drugs seems likely.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7793236     DOI: 10.1111/j.1600-0404.1995.tb00434.x

Source DB:  PubMed          Journal:  Acta Neurol Scand        ISSN: 0001-6314            Impact factor:   3.209


  20 in total

Review 1.  Typical absence seizures and their treatment.

Authors:  C P Panayiotopoulos
Journal:  Arch Dis Child       Date:  1999-10       Impact factor: 3.791

2.  Valproate efficacy in absence seizures is hard to beat: lamotrigine comes close.

Authors:  Bassel W Abou-Khalil
Journal:  Epilepsy Curr       Date:  2005 Mar-Apr       Impact factor: 7.500

3.  Ethosuximide, sodium valproate or lamotrigine for absence seizures in children and adolescents.

Authors:  Francesco Brigo; Stanley C Igwe; Simona Lattanzi
Journal:  Cochrane Database Syst Rev       Date:  2019-02-08

Review 4.  Pharmacokinetic interactions of the new antiepileptic drugs.

Authors:  B Rambeck; U Specht; P Wolf
Journal:  Clin Pharmacokinet       Date:  1996-10       Impact factor: 6.447

5.  Effects of combined lamotrigine and valproate on basal and stimulated extracellular amino acids and monoamines in the hippocampus of freely moving rats.

Authors:  Shagufta Ahmad; Leslie J Fowler; Peter S Whitton
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2005-01-20       Impact factor: 3.000

Review 6.  Treatment of typical absence seizures and related epileptic syndromes.

Authors:  C P Panayiotopoulos
Journal:  Paediatr Drugs       Date:  2001       Impact factor: 3.022

Review 7.  Harnessing the clinical potential of antiepileptic drug therapy: dosage optimisation.

Authors:  E Perucca; O Dulac; S Shorvon; T Tomson
Journal:  CNS Drugs       Date:  2001       Impact factor: 5.749

Review 8.  Drug treatment of epilepsy in elderly people: focus on valproic Acid.

Authors:  Linda J Stephen
Journal:  Drugs Aging       Date:  2003       Impact factor: 3.923

9.  Comparison and effects of acute lamotrigine treatment on extracellular excitatory amino acids in the hippocampus of PTZ-kindled epileptic and PTZ-induced status epilepticus rats.

Authors:  Yan Deng; Minghuan Wang; Wei Wang; Chao Ma; Nongyue He
Journal:  Neurochem Res       Date:  2012-12-11       Impact factor: 3.996

10.  Lamotrigine and valproate pharmacokinetics interactions in epileptic patients.

Authors:  Mladena Lalic; Jelena Cvejic; Jovan Popovic; Ksenija Bozic; Svetlana Golocorbin-Kon; Hani Al-Salami; Momir Mikov
Journal:  Eur J Drug Metab Pharmacokinet       Date:  2009 Apr-Jun       Impact factor: 2.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.